Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siplizumab induction in AILD liver transplant
NCT06455280Phase 1Recruiting
- Start
- Sep 2024
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of siplizumab in Liver transplant rejection, autoimmune hepatitis (AIH) and Primary Sclerosing Cholangitis (PSC). Primary endpoint: Serious infection in the first month post-transplant at 1 month. Started Sep 2024; status: recruiting.
02
Drugs
siplizumab
03
Conditions
Liver transplant rejectionautoimmune hepatitis (AIH)Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT06455280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06455280.